STRADA抗体STRADA兔多抗抗体Serological
ly defined breast cancer antigen NY-BR-96 antibody抗体STRADA Antibody抗体- ￥440 - 1320
- CUSABIO
- CN
- CSB-PA745759ESR1HU
- 2025年07月11日
- ELISA, IHC; Recommended dilution: IHC:1:20-1:200
- Rabbit
- Human
企业认证
相关产品推荐更多 >
ZNF460抗体ZNF460兔多抗抗体/抗体ZNF460 Antibody抗体
￥2024
DLG5抗体DLG5兔多抗抗体Placenta and prostate DLG antibody抗体DLG5 Antibody抗体
￥440
ABCC1抗体ABCC1一抗抗体Multiple drug resistance protein 1 antibody抗体ABCC1 Antibody抗体
￥1100
/抗体/兔多抗抗体/抗体VPS16 Antibody, Biotin conjugated抗体
￥880
IL1B抗体IL1B兔多抗抗体Pro interleukin 1 beta antibody抗体IL1B Antibody, HRP conjugated抗体
￥880
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Recombinant Human STE20-related kinase adapter protein alpha protein (25-210AA)
- 亚型：
IgG
- 形态：
Liquid
- 保存条件：
Upon receipt, store at -20℃ or -80℃. Avoid repeated freeze.
- 克隆性：
Polyclonal
- 标记物：
Non-conjugated
- 适应物种：
Human
- 保质期：
6个月
- 抗原来源：
Homo sapiens (Human)
- 目录编号：
Q7RTN6
- 级别：
优
- 库存：
200
- 供应商：
武汉华美生物工程有限公司
- 宿主：
Rabbit
- 应用范围：
ELISA, IHC; Recommended dilution: IHC:1:20-1:200
- 浓度：
>95%,Antigen Affinity Purified
- 靶点：
STRADA
- 抗体英文名：
STRADA Antibody
- 抗体名：
STRADA antibody;LYK5 antibody;STRAD antibody;STE20-related kinase adapter protein alpha antibody;STRAD alpha antibody;STE20-related adapter protein antibody;Serologically defined breast cancer antigen NY-BR-96 antibody
- 规格：
100μl/50μl/20μl
| 规格： | 100μl | 产品价格： | ￥1320.0 |
|---|---|---|---|
| 规格： | 50μl | 产品价格： | ￥880.0 |
| 规格： | 20μl | 产品价格： | ￥440.0 |
保存缓冲液
PBS with 0.02% sodium azide, 50% glycerol, pH7.3.功能
Pseudokinase which, in complex with CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta), binds to and activates STK11/LKB1. Adopts a closed conformation typical of active protein kinases and binds STK11/LKB1 as a pseudosubstrate, promoting conformational change of STK11/LKB1 in an active conformation.风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Development and Activities of the BR96-Doxorubicin Immunoconjugate
radioisotopes to tumors in rodents. The promise of this approach received a strong boost when K�hler and Milstein introduced monoclonal antibody (MAb) technology in the 1970s (1 ). However, the clinical success of unmodified MAbs or MAbs conjugated to drugs
Quantitative Angiogenesis in Breast Cancer
VIII-related antigen at high power over a defined field area. The generation of more sensitive and specific markers—in particular antibodies to CD34—together with the use of a Chalkley eyepiece graticule have improved the objectivity of the assessment
PEGylation of Antibody Fragments to Improve Pharmacodynamics and Pharmacokinetics
antibody fragments of 25 and 50kDa respectively to target human breast cancer cells. Purification and analysis of immunoreactivity of the PEGylated immunoconjugates is also explained.
技术资料暂无技术资料 索取技术资料
